drugset / Trial / NCT07093476

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

NCT07093476

Phase 3 Recruiting 171 enrolled Celltrion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Timeline

Start
2025-07-18
Primary completion
2026-12
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule Oral
Comparator Alogliptin Unknown Oral
Comparator Metformin Small molecule Oral